We are live on ! Find out more
AZN icon

AstraZeneca
AZN

331 hedge funds and large institutions have $5.84B invested in AstraZeneca in 2013 Q2 according to their latest regulatory filings, with 331 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

227% more call options, than puts

Call options by funds: $100M | Put options by funds: $30.6M

9.87% more ownership

Funds ownership: 0% → 9.87% (+9.9%)

Holders
331
Holders Change
+331
Holders Change %
–
% of All Funds
10.8%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.16%
New
331
Increased
–
Reduced
–
Closed
–
Calls
$100M
Puts
$30.6M
Net Calls
+$69.5M
Net Calls Change
+$69.5M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$1.12B +$1.2B +23,618,117 New
Allianz Asset Management
2
Allianz Asset Management
Germany
$607M +$654M +12,843,122 New
Arrowstreet Capital
3
Arrowstreet Capital
Massachusetts
$291M +$314M +6,161,726 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$289M +$312M +6,120,252 New
U
5
UBS
Switzerland
$247M +$266M +5,231,528 New
Hotchkis & Wiley Capital Management
6
Hotchkis & Wiley Capital Management
California
$234M +$252M +4,944,742 New
MAA
7
Managed Account Advisors
New Jersey
$221M +$238M +4,666,373 New
SCCM
8
Schafer Cullen Capital Management
New York
$176M +$189M +3,713,916 New
Federated Hermes
9
Federated Hermes
Pennsylvania
$174M +$188M +3,688,423 New
Renaissance Technologies
10
Renaissance Technologies
New York
$162M +$174M +3,425,700 New
EIP
11
Epoch Investment Partners
New York
$149M +$161M +3,155,346 New
LBA
12
Letko, Brosseau & Associates
Quebec, Canada
$144M +$155M +3,035,839 New
BIP
13
Brandes Investment Partners
California
$104M +$112M +2,206,222 New
Ameriprise
14
Ameriprise
Minnesota
$90.5M +$97.4M +1,913,520 New
Capital World Investors
15
Capital World Investors
California
$79M +$85M +1,670,000 New
OSAM
16
O'Shaughnessy Asset Management
Connecticut
$76.7M +$82.5M +1,619,461 New
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$75M +$80.8M +1,586,673 New
Wells Fargo
18
Wells Fargo
California
$71.8M +$77.3M +1,517,373 New
CCM
19
Cullen Capital Management
New York
$71.6M +$77.1M +1,513,500 New
CS
20
Credit Suisse
Switzerland
$60.8M +$65.4M +1,284,827 New
Neuberger Berman Group
21
Neuberger Berman Group
New York
$55.7M +$59.9M +1,176,944 New
BA
22
BlackRock Advisors
Delaware
$47.1M +$50.7M +996,100 New
DM
23
Deerfield Management
New York
$43.9M +$47.3M +928,000 New
Morgan Stanley
24
Morgan Stanley
New York
$43.8M +$47.1M +925,190 New
IG
25
ING Group
Netherlands
$42.6M +$45.9M +900,921 New
1
2 3 4 5

AZN Hedge Fund Activity: Q2 2013 in Review

331 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2013, worth a combined $5.84B.

Buyers outnumbered sellers: 331 funds opened new AZN positions and 0 closed out — a net gain of 331 holders — while 0 added to existing stakes and 0 trimmed.

  • 331 institutional investors held AstraZeneca (AZN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $5.84B of AstraZeneca stock for Q2 2013.
  • 331 funds opened new AstraZeneca positions in Q2 2013 and 0 closed out, a net change of +331 holders.

Based on aggregated 13F filings for Q2 2013.